Endocrine, metabolic & immune disorders drug targets
Bridging Glycemic and Lipid Control: Effects of Dapagliflozin in Co-Morbid Diabetes and Heart Failure - A Randomized Controlled Trial.
Laxmi Sankalpa Bhaganagarapu, Sarumathy Sundararajan, Vengatesh Munusamy
Published: 202610.2174/0118715303398749251027044323
Abstract
INTRODUCTION: Dapagliflozin, an SGLT2 inhibitor developed for Type 2 Diabetes Mellitus (T2DM), has shown multiple cardiovascular benefits. This study evaluated its effects on lipid profile and IR pattern in South Indian patients with T2DM and Heart F…
Preview only. Read the full abstract at the source